David Gerkin Friday, 11/22/13 12:25:05 PM Re: None Post # of 1310 $12,000 in available cash as per the last 10Q. Potential for crash & burn is very high. Burned through the $200k grant and now running on fumes. Correvio earned $30million+ per year for global sales of aggrastat...not a serious contender. And they got bought out by a company with a market cap around $70 million. Hope the annual shareholder meeting (11/26) goes well, if any shareholders show up. Have to vote on their accountants compensation. By the way, bankrupt Savient Pharmaceuticals shares a similar market valuation with Medicure. Bring on another reverse split.